Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have earned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $38.33.

A number of analysts have weighed in on the company. Bank of America increased their price objective on Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price target on shares of Denali Therapeutics in a report on Wednesday, September 4th. Wedbush dropped their price objective on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Cantor Fitzgerald cut shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday. Finally, Citigroup lifted their target price on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a report on Friday, August 2nd.

Insider Activity

In related news, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the sale, the director now owns 29,096 shares of the company’s stock, valued at approximately $844,656.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. EP Wealth Advisors LLC acquired a new stake in Denali Therapeutics in the first quarter valued at $831,000. Edgestream Partners L.P. purchased a new stake in shares of Denali Therapeutics in the 1st quarter worth about $2,301,000. Susquehanna Fundamental Investments LLC acquired a new stake in Denali Therapeutics in the 1st quarter valued at about $4,330,000. Swiss National Bank increased its holdings in Denali Therapeutics by 0.7% during the 1st quarter. Swiss National Bank now owns 218,200 shares of the company’s stock valued at $4,477,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Bayesian Capital Management LP acquired a new position in Denali Therapeutics during the first quarter worth about $447,000. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $26.73 on Wednesday. Denali Therapeutics has a 1-year low of $14.56 and a 1-year high of $32.13. The stock has a market cap of $3.81 billion, a P/E ratio of -27.84 and a beta of 1.38. The firm has a fifty day moving average price of $26.03 and a 200 day moving average price of $22.19.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, August 1st. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.09. The business had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $10.00 million. During the same period in the previous year, the company posted $1.30 earnings per share. Denali Therapeutics’s quarterly revenue was down 99.7% on a year-over-year basis. Sell-side analysts expect that Denali Therapeutics will post -2.54 EPS for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.